Market News / Story
Biohaven licenses IgG degrader portfolio to Japan’s Ono
Seeking Alpha ·
Seeking Alpha reports: Biohaven on Thursday announced an agreement with Ono Pharmaceutical under which the Japanese drugmaker will develop and commercialize the company’s MoDE pan IgG degrader portfolio in several Asian countries. Designed to degrade disease-causing proteins in the extracellular space, the MoDE portfolio includes Biohaven’s investigational treatments BHV-1300, BHV-1310, and BHV-1320. As part of the deal, Osaka-based Ono will buy an exclusive license to develop and…